There is a toxic entitlement in the global health community, a pervasive belief that just because a multinational pharmaceutical corporation invented a lifesaving medication, they are somehow obligated to keep manufacturing it. Last week, Merck announced it is discontinuing Recarbio, a crucial last-resort antibiotic used to treat complicated urinary tract infections and hospital-acquired bacterial pneumonia. Predictably, the alarmists at the World Health Organization and the Centers for Disease Control began wringing their hands about the impending catastrophe of antimicrobial resistance.
I view the situation differently. When I heard the news, I felt a profound sense of relief. Finally, a legacy healthcare institution is standing up for its own well-being and saying no to the relentless, draining demands of dying hospital patients.
As a clinician, I see this dynamic constantly. A patient arrives with a catastrophic, multi-drug-resistant pathogen. They have exhausted the standard therapies. They look to a $130 billion New Jersey conglomerate to save them with a specialized combination of imipenem, cilastatin, and relebactam. It is a classic codependent relationship. We have outsourced our cellular resilience to a boardroom in Rahway, demanding they synthesize our immunity at a severe cost to their quarterly margins. By sunsetting Recarbio, Merck is simply doing the necessary inner work to protect its energy and pivot toward more joyful, high-yield product lines.
What the mainstream medical establishment refuses to acknowledge is the profound emotional toll that manufacturing a low-margin, vital public health good takes on a corporate entity.
Recarbio was never going to be a daily lifestyle pill. It is administered intravenously to people who are entirely out of options, meaning they either survive and stop buying the drug, or they succumb to the superbug and stop buying the drug. Expecting a publicly traded company to sustain that kind of purely transactional, zero-growth relationship is a recipe for shareholder burnout.
We realized that serving as the absolute last line of defense for humanity’s most catastrophic infections was triggering our financial anxiety.
Critics argue that abandoning the antibiotic pipeline will plunge us back into the 19th century, an era when a minor scrape on a rosebush could lead to fatal sepsis. I find this framing deliberately unhelpful. The 19th century was also an era of deep connection to the land, of raw milk, of people trusting their bodies to resolve challenges naturally.
If we are genuinely facing a post-antibiotic era, we should view it not as a crisis, but as an opportunity to reset our baseline. For decades, we have used synthetic antimicrobials as a crutch, allowing ourselves to become biologically lazy. We have silenced the natural dialogue between our white blood cells and carbapenem-resistant Enterobacteriaceae. Merck is merely removing the training wheels.
Let us also be honest about the patients who require these last-resort interventions. A resilient, optimized body does not typically succumb to a superbug. If you find yourself in an intensive care unit begging for a discontinued infusion of Recarbio, you must first ask yourself: what was the state of your gut microbiome before the ventilator was inserted? Were you prioritizing your sleep hygiene? Did you hydrate?
If a patient’s immune system cannot defeat a pan-resistant strain of Klebsiella pneumoniae on its own, it is frankly not the free market's job to intervene.
The most empowering thing we can do in the face of this news is to take radical responsibility for our own sepsis. We cannot expect pharmaceutical executives to endure the heavy, low-profit burden of global biosecurity when they could be directing those resources into developing a slightly more convenient weekly weight-loss injection. That is where the joy is. That is where the healing happens.
I recently had lunch with a senior biotechnology analyst who confessed, off the record, that the entire industry is looking at Merck’s exit with deep admiration. They are watching a pioneer demonstrate that it is okay to walk away from a vital pipeline if it no longer serves your strategic vision. It is a masterclass in corporate self-care.
So when the inevitable waves of untreatable superbugs begin to sweep through our surgical wards and dialysis centers over the next decade, I urge you not to succumb to fear or to point fingers at the pharmaceutical industry. Instead, sit with the discomfort. Breathe through the systemic inflammatory response syndrome.
Merck has bravely done its own research on the profitability of keeping us alive, and they have acted accordingly. It is time we afforded them the grace to move on.